Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
CNBX Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
CNBX
Over the counter
8731
https://cannabics.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for CNBX Pharmaceuticals Inc
CNBX to Enter the Cancer Immunotherapy Market After Acquiring a Controlling Interest in TaGeza Biopharma
- Nov 8th, 2022 2:00 pm
CNBX Files New PCT Patent Application For Cannabinoids-Based Neoadjuvant Cancer Therapy
- Oct 18th, 2022 1:10 pm
CNBX Patent Application "Composition and Method for Treating Cancer with Cannabinoids" Enters National Phase in US and Israel
- Oct 13th, 2022 12:55 pm
CNBX Peer-reviewed Study: "Possible Future Therapeutic Value" for CNBX Proprietary Drug Candidate
- Sep 29th, 2022 1:10 pm
CNBX Pharmaceuticals Announces New Patent Granted in Australia
- Sep 28th, 2022 1:26 pm
CNBX Pharmaceuticals Granted Patent in Hong Kong
- May 5th, 2022 1:11 pm
Scroll